BiomX (PHGE) Set to Announce Quarterly Earnings on Wednesday

BiomX (NYSEAMERICAN:PHGE) is expected to release its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to announce earnings of ($703.00) per share and revenue of $0.33 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

BiomX (NYSEAMERICAN:PHGE) last announced its earnings results on Wednesday, August 19th. The company reported ($3.70) earnings per share for the quarter. The business had revenue of $0.33 million during the quarter. On average, analysts expect BiomX to post ($58.50) EPS for the current fiscal year and ($60.10) EPS for the next fiscal year.

BiomX Stock Performance

Shares of NYSEAMERICAN:PHGE remained flat at $1.85 during midday trading on Wednesday. 3,333,670 shares of the stock traded hands, compared to its average volume of 364,372. BiomX has a 1-year low of $1.19 and a 1-year high of $122.93. The company has a quick ratio of 0.24, a current ratio of 0.24 and a debt-to-equity ratio of 0.02. The company’s 50-day moving average price is $1.76 and its 200 day moving average price is $17.67. The stock has a market cap of $4.94 million, a P/E ratio of -0.58 and a beta of 1.33.

BiomX Company Profile

BiomX Inc is a clinical-stage biotechnology company developing precision therapies that target harmful bacteria while seeking to preserve beneficial microorganisms. The company’s platform uses naturally occurring bacteriophages, or viruses that selectively infect and destroy specific bacteria, to address diseases associated with the microbiome.

BiomX has focused its research and development programs on conditions including cystic fibrosis and inflammatory bowel disease. Its pipeline has included BX004, an inhaled phage therapy designed to target Pseudomonas aeruginosa in the lungs of people with cystic fibrosis, and BX211, an investigational therapy intended to target disease-associated bacteria in the gastrointestinal tract.

Founded in Israel and with roots connected to research conducted at the Weizmann Institute of Science, BiomX has operated as a publicly traded biotechnology company since completing a business combination in 2019.